STALLERGENES GREER |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| - EUR | -.--% |
|
+0.14% | +29.68% |
| 2023 | Nestle Reportedly May Sell Peanut Allergy Therapy to Stallergenes | CI |
| 2023 | Stallergenes Greer Ltd Initiates European Paediatric Phase III Study with Staloral Birch | CI |
| Sales 2020 | 304M 324M | Sales 2021 | 328M 349M | Capitalization | 724M 771M |
|---|---|---|---|---|---|
| Net income 2020 | 33M 35.13M | Net income 2021 | 60M 63.87M | EV / Sales 2020 | 3.16 x |
| Net Debt 2020 | 237M 253M | Net Debt 2021 | 249M 265M | EV / Sales 2021 | 2.97 x |
| P/E ratio 2020 |
21.5
x | P/E ratio 2021 |
11.9
x | Employees | - |
| Yield 2020 * |
-
| Yield 2021 |
-
| Free-Float | 0% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| Managers | Title | Age | Since |
|---|---|---|---|
Amer Jaber
COO | Chief Operating Officer | - | 18-12-31 |
Daniel Smith
CTO | Chief Tech/Sci/R&D Officer | - | 16-04-10 |
Nicola Lamacchia
BRD | Director/Board Member | - | 17-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Nunzio Antonelli
BRD | Director/Board Member | - | 15-11-09 |
Nicola Lamacchia
BRD | Director/Board Member | - | 17-02-28 |
Stallergenes Greer Ltd is a United States-based holding company. The Company is a healthcare company. Its engaged in the diagnosis and treatment of allergies through the development and commercialization of allergen immunotherapy products and services. It also engaged in distribution of products and services.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| +29.68% | 0 | |
| +10.08% | 9.12B | |
| -15.94% | 4.8B | |
| +18.47% | 3.72B | |
| +1.89% | 3.8B | |
| +25.43% | 2.58B | |
| -24.63% | 2.36B | |
| -29.37% | 2.11B | |
| +2.55% | 1.86B | |
| -0.50% | 1.64B |
- Stock Market
- Equities
- STAGR Stock
